Systemic metabolic disease: How multi-receptor drug strategies reflect structural gaps in prevention and equity
Original framing: “[Comment] Multireceptor modulation in metabolic disease: are more targets better?” — The Lancet
Future scenarios must account for the unintended consequences of multi-receptor drugs, including ecological harm from pharmaceutical pollution and the potential for drug-resistant metabolic disorders. Modeling should prioritize prevention over treatment, integrating urban design, food policy, and community health systems to reduce disease burden. Additionally, future health systems must address the intersectional inequities that make marginalized groups both more vulnerable to metabolic disease and less likely to benefit from high-cost therapies.
The Lancet’s framing of metabolic disease as a 'target-rich' opportunity for pharmaceutical innovation reflects a biomedical paradigm that medicalizes social problems while obscuring the structural forces driving disease—colonial food systems, corporate agribusiness, and inequitable urban design.
This approach prioritizes profit-driven solutions over prevention, disproportionately harming marginalized communities who bear the brunt of metabolic dysfunction yet lack access to emerging therapies. Indigenous and cross-cultural models, which address health through land, community, and holistic practices, offer low-cost, sustainable alternatives to the pharmaceutical treadmill. Meanwhile, the push for multi-receptor drugs risks creating a polypharmacy trap, where patients become dependent on increasingly complex regimens while the root causes of disease fester. True systemic change requires dismantling the obesogenic environment, centering marginalized voices in policy and care, and rebalancing the relationship between humans, land, and health—before the next 'miracle drug' distracts us from the work that actually matters.